...
首页> 外文期刊>Journal of Materials Chemistry, B. materials for biology and medicine >Fabrication of hydroxyapatite/chitosan composite hydrogels loaded with exosomes derived from miR-126-3p overexpressed synovial mesenchymal stem cells for diabetic chronic wound healing
【24h】

Fabrication of hydroxyapatite/chitosan composite hydrogels loaded with exosomes derived from miR-126-3p overexpressed synovial mesenchymal stem cells for diabetic chronic wound healing

机译:载有miR-126-3p过表达的滑膜间充质干细胞的脂质体负载羟基磷灰石/壳聚糖复合水凝胶用于糖尿病慢性伤口愈合

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The exploration of an effective diabetic chronic wound healing process still remains a great challenge. Herein, we used gene overexpression technology to obtain synovial mesenchymal stem cells (SMSCs) and the miR-126-3p highly expressed SMSCs (SMSCs-126). The exosomes derived from miR-126-3p overexpressed SMSCs (SMSCs-126-Exos) with a particle size of 85 nm were encapsulated in hydroxyapatite/chitosan (HAP-CS) composite hydrogels (HAP-CS-SMSCs-126-Exos) as wound dressings. The SMSCs-126-Exos, CS and low-crystallinity HAP nanorods with a length of 200 nm and a diameter of 50 nm are uniformly dispersed within the whole composite hydrogel. The HAP-CS-SMSCs-126-Exos possess the controlled release property of SMSCs-126-Exos for at least 6 days. The released SMSCs-126-Exos nanoparticles stimulate the proliferation and migration of human dermal fibroblasts and human dermal microvascular endothelial cells (HMEC-1). At the same time, the migration and capillary-network formation of HMEC-1 are promoted through the activation of MAPK/ERK and PI3K/AKT. In vivo tests demonstrate that the HAP-CS-SMSCs-126-Exos successfully promote wound surface re-epithelialization, accelerate angiogenesis, and expedite collagen maturity due to the presence of HAP, CS and SMSCs-126-Exos. Therefore, the HAP-CS-SMSCs-126-Exos possess great potential application for diabetic chronic wound healing, and especially provide the possibility of using exosomes derived from modified cells as a new approach to bring wonderful functionality and controllability in future chronic wound therapy.
机译:探索有效的糖尿病慢性伤口愈合过程仍然是巨大的挑战。本文中,我们使用基因过表达技术获得滑膜间充质干细胞(SMSCs)和miR-126-3p高表达SMSC(SMSCs-126)。将miR-126-3p过表达的SMSC(SMSCs-126-Exos)的外泌体包裹在羟基磷灰石/壳聚糖(HAP-CS)复合水凝胶(HAP-CS-SMSCs-126-Exos)中,粒径为85 nm。伤口敷料。长度为200 nm,直径为50 nm的SMSCs-126-Exos,CS和低结晶度HAP纳米棒均匀分散在整个复合水凝胶中。 HAP-CS-SMSCs-126-Exos具有SMSCs-126-Exos的控释特性至少6天。释放的SMSCs-126-Exos纳米颗粒刺激人皮肤成纤维细胞和人皮肤微血管内皮细胞(HMEC-1)的增殖和迁移。同时,通过激活MAPK / ERK和PI3K / AKT促进HMEC-1的迁移和毛细管网络的形成。体内测试表明,由于存在HAP,CS和SMSCs-126-Exos,HAP-CS-SMSCs-126-Exos成功地促进了伤口表面的上皮形成,加速了血管生成并加速了胶原蛋白的成熟。因此,HAP-CS-SMSCs-126-Exos在糖尿病慢性伤口愈合中具有巨大的潜在应用,特别是提供了使用源自修饰细胞的外泌体作为新方法为将来的慢性伤口治疗带来出色功能和可控性的可能性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号